Follow-up on Rituximab treatment for children's nephrotic syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the efficacy and safety of rituximab in children diagnosed with refractory nephrotic syndrome. It involves a retrospective analysis of clinical data from patients treated with rituximab at the First Affiliated Hospital of Xiamen University over a period of at least one year. Key outcomes include relapse-free survival, frequency of relapses, and adverse reactions associated with the treatment. The study also compares different treatment regimens and analyzes risk factors for recurrence of nephropathy post-treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Children clinically diagnosed with FRNS/SDNS/SRNS with complete clinical data;
* age \< 18 years old;
* For the first time using RTX treatment, and used in nephrotic syndrome ease;
* The follow-up for 1 year or more.

Exclusion Criteria:

* Congenital or infantile nephrotic syndrome, secondary nephrotic syndrome (such as lupus nephritis, IgA nephropathy, purpura nephritis, hepatitis B nephritis, etc.);
* Active stage of hepatitis, complicated with severe infection, severe deficiency of immune response, malignant diseases;
* Estimated glomerular filtration rate (GFR) \<60mL/min/1.73m2.

Where it's running

• First affiliated hospital of xiamen university
  Xiamen, Fujian, China Recruiting

Study contacts

• Study coordinator: Bai HaiTao, doctor
• Email: baihaitao@163.com
• Phone: 13779985336

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BTKi‑rituximab induction followed by glofitamab consolidation for high‑risk newly diagnosed mantle cell lymphoma

  This will test whether giving glofitamab after initial BTKi plus rituximab helps control high‑risk, newly diagnosed mantle cell lymphoma.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07257055

• Combining belimumab and rituximab for treating primary membranous nephropathy

  This study is testing if combining two medications, belimumab and rituximab, can help adults with primary membranous nephropathy feel better and achieve remission more effectively than using rituximab alone.

  Recruiting at 20 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 19 other locations · NCT03949855

• Combining Rituximab and Cyclosporine for Membranous Nephropathy

  This study tests if combining two medications, rituximab and cyclosporine, can help people with membranous nephropathy improve their kidney function and reduce protein in their urine.

  Recruiting at 2 sites Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland and 1 other locations · NCT00977977

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Chidamide, Lenalidomide, and Rituximab as induction therapy for newly diagnosed elderly or unfit double-expressor DLBCL

  This trial tests whether the combo of chidamide, lenalidomide, and rituximab can help treat newly diagnosed double-expressor DLBCL in people who are elderly or not fit for standard chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07884708

• Rituximab plus Cyclosporine for Primary Membranous Nephropathy

  This study tests whether adding Cyclosporine to Rituximab helps people with primary membranous nephropathy achieve remission of heavy protein in the urine faster.

  Recruiting Phase 2/3 Peking University First Hospital · Beijing · NCT07861204

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.